Abstract

) Specific Aim 1. To provide packaged viral vectors for laboratory research in the Stem Cell Biology and Transplant Program. Retrovirus vectors and lentivirus vectors will be constructed either in the laboratory of the investigator or in the Vector Core Laboratory. The Vector Core will then use the vector construct DNA in transfections to generate viral vector, also conducting necessary quality control analyses (titer, helper assays), thus providing the final vector product to the investigator for experiments described in each individual section of this Program Project Grant proposal.
Specific Aim 2. To provide clinical-grade retro viral vectors for human trials conducted as a part of the Stem Cell Biology and Transplant Program. Clinical-grade retro viral vector will be produced under cGMP conditions at the Molecular and Cellular Therapeutics Facility, St. Paul Campus of the University of Minnesota, for use in human clinical trials to be carried out as a part of the Stem Cell Biology Research Program. Clinical-grade vectors planned for production include marking vector for human hematopoietic and mesodermal progenitor cells (Projects 2, 3 and 5), vectors transducing drug resistance genes (Project 3), and vectors transducing the human alpha-Liduronidase gene (Project 5).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-08
Application #
6652741
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-08-26
Project End
2003-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455

  Publications

Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Pennell, Christopher A; Barnum, Jessie L; McDonald-Hyman, Cameron S et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther 26:1423-1434
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933

Showing the most recent 10 out of 395 publications